No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88
Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88